Skip to Main Content

Despite large amounts of taxpayer funding, dozens of the largest U.S. universities failed to commit to policies ensuring that essential medicines and health technologies generated by their labs would be equally accessible around the globe, a new analysis finds.

Of the 60 universities that were examined, only 22% committed to specific global access licensing strategies and just 12% adopted licensing that places a priority on generic production of medicines for lower-income countries, according to the Universities Allied Essential Medicines, an organization led by medical students who seek to improve affordable access worldwide.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!